Abliva AB Interim Report January – June 2021

Second quarter summary

Phase 1a/b study: positive placebo-controlled safety data for KL1333 and the first evidence of efficacy 

Important events second quarter (Apr - Jun 2021)

  • Data from the Phase 1a/b clinical study of KL1333 was released and confirmed the safety and pharmacokinetic profile of the drug. In addition, in a cohort of eight patients (six dosed with KL1333, two with placebo), there were signs of efficacy across well-established relevant clinical endpoints including two patient-reported fatigue endpoints and a functional endpoint.
  • Extraordinary General Meeting was held on 29 April 2021. 
  • The directed share issue, approved by the Extraordinary General Meeting, was completed. The Company raised approx. SEK 76 million after deduction of issue costs.
  • Annual General Meeting was held on 20 May 2021.

Important events after the reporting period

  • The validation study of fatigue as an endpoint, for the KL1333 Phase 2/3 study, was completed.

Financial information

April-June 2021*

  • Net revenues: SEK 18,000 (97,000)
  • Other operating income: SEK 0,000 (34,000) 
  • Loss before tax: SEK 30,314,000 (20,312,000) 
  • Loss per share: SEK 0.08 (0.09)
  • Diluted loss per share: SEK 0.08 (0.09) 

January-June 2021*

  • Net revenues: SEK 18,000 (105,000)
  • Other operating income: SEK 0,000 (34,000) 
  • Loss before tax: SEK 51,770,000 (36,849,000) 
  • Loss per share: SEK 0.13 (0.18)
  • Diluted loss per share: SEK 0.13 (0.18)

* APM Alternative perfomance measures, see definition on page 20.

The complete Interim report is available for download below and through the company's website www.abliva.com

Source: MFN

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Dagens industri som e-tidning redan kvällen innan

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr


Redan prenumerant?